Letermovir is an antiviral active pharmaceutical ingredient used to prevent cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those undergoing allogeneic stem cell transplants. It is a research compound developed for pharmaceutical manufacturing and supply.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 917389-32-3
Triacetylganciclovir
pharmaceutical raw material
Inosine pranobex
pharmaceutical raw material
Foscarnet
pharmaceutical raw material
Acyclovir alaninate
pharmaceutical raw material
Cefdinir
pharmaceutical raw material
Vemurafenib
pharmaceutical raw material
Lithium citrate
pharmaceutical raw material
Phenothiazine
pharmaceutical raw material
2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
FWYSMLBETOMXAG-QHCPKHFHSA-N
COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O